CareDx (CDNA) Tops Q4 EPS by 41c, provides guidance

CareDx (NASDAQ: CDNA) reported Q4 EPS of $0.18, $0.41 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $86.6 million versus the consensus estimate of $82.18 million.

GUIDANCE:

CareDx sees FY2025 revenue of $365-375 million, versus the consensus of $370 million.
CareDx expects full year 2025 adjusted EBITDA gain to be in the range of $29 million to $33 million.

For earnings history and earnings-related data on CareDx (CDNA) click here.

You May Also Be Interested In

• US's Greer Says Usmca Shifting To Rolling Talks, No Renewal - Bloomberg
• Qualcomm (QCOM) spreader of July 2 weekly 212.50 and July 10 weekly 192.50 calls
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance